pharma · Solid Tumors · RAS Mutation · KTTA
Pasithea Therapeutics
Pasithea Therapeutics is a pharma organization headquartered in Miami Beach, USA. It trades on NYSE under ticker KTTA. Primary therapeutic focus areas include Solid Tumors, RAS Mutation, NF1 Mutation. NovaPharmaNews link
Miami Beach, USA HQ
2020 Founded
11 Employees
Public company Type
KTTA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Miami Beach, USA
- Founded
- 2020
- Employees
- 11
- Programs
- 3
- Drugs
- 6
- Patents
- 0
A Phase 1 Open-label Study to Assess the Safety for Solid Tumors
Phase 1 · other · Solid Tumors
A Phase 1 Open-label Study to Assess the Safety for Solid Tumors for Solid Tumors is a Phase 1 program (other) at Pasithea Therapeutics with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pasithea Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- Solid Tumors
- Status
- active
- Trials
- 1